ARL6

Across TCGA pan-cancer cohorts, ARL6 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ARL6’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ARL6 RNA is repressed in tumor relative to normal tissue. In most cancer types ARL6 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LUSC, and LUAD are the cancer types where ARL6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.945	<.001	10	view →
LUSC	All	III,IV	−1.351	<.001	8	view →
LUAD	Female	III,IV	−1.274	<.001	8	view →
LIHC	Male	All	+0.582	<.001	8	view →
KIRP	All	All	−0.406	.004	6	view →
KIRC	Male	II,III,IV	−0.402	.001	6	view →
CHOL	Male	All	+1.593	<.001	4	view →
READ	Male	All	+0.696	.045	2	view →
UCEC	All	All	−0.549	.013	2	view →
HNSC	Male	IV	+0.635	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

ARL6–THCA

Open the THCA breakdown →